financetom
Business
financetom
/
Business
/
Rivian's Planned JV With Volkswagen to be 'Game Changer' for US EV Maker, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rivian's Planned JV With Volkswagen to be 'Game Changer' for US EV Maker, Wedbush Says
Jun 26, 2024 10:48 AM

01:39 PM EDT, 06/26/2024 (MT Newswires) -- Rivian Automotive's ( RIVN ) planned joint venture with German car manufacturer Volkswagen Group is likely to be a "game changer" for the US electric vehicle maker, Wedbush Securities said Wednesday.

Late Tuesday, the companies said they planned to form a joint venture to create new software-defined vehicle platforms, to be used in their future EVs. Volkswagen initially intends to invest $1 billion in Rivian, with up to $4 billion in planned additional investment as part of the deal.

Rivian expects the partnership to notably expand market applications for its software and related zonal electrical architecture and create a "robust" capital roadmap to support future growth, Chief Executive RJ Scaringe said on a conference call late Tuesday, according to a Capital IQ transcript. "We believe the opportunity ahead is significant."

The company's shares were up nearly 24% in Wednesday afternoon trade.

The partnership will help bring "the best solutions to our vehicles faster and at lower cost," Volkswagen CEO Oliver Blume said in a statement. Rivian and Volkswagen plan to roll out vehicles taking advantage of the technology created within the joint venture in the second half of the decade, the companies said.

"This is a core game changer for Rivian and changes the capital structure of the company looking ahead for the story and (Wall Street's) view at a key time," Wedbush analysts, including Daniel Ives, said in a Wednesday note to clients. The partnership is expected to provide the company the capital required for the ramp of its R2 vehicles, as well as for its midsize EV platform at its plant in Georgia, the analysts wrote.

In addition to the $5 billion of capital proceeds, Rivian expects incremental benefits via "material" cost savings, operating expense efficiencies and future revenue opportunities tied to the joint venture, Chief Financial Officer Claire McDonough told analysts.

The companies expect the completion of the joint venture formation in the fourth quarter.

"While this is an exciting announcement for us to see, in the eyes of the Street, the focus will still remain mostly on the R1 execution plans, production, optimization, the Georgia plant, and the profitability story for Rivian over the next (quarter to 12 months)," the Wedbush analysts said.

The brokerage raised its price target on the EV maker's stock to $20 from $15 while maintaining its outperform rating.

Price: 14.45, Change: +2.49, Percent Change: +20.78

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gunvor's head of US gasoline trading Sinenko departs for rival
Gunvor's head of US gasoline trading Sinenko departs for rival
Aug 2, 2024
NEW YORK, Aug 2 (Reuters) - Dmitri Sinenko, head of U.S. gasoline trading and executive committee member at Gunvor, is leaving the Swiss trader to join Russian rival Litasco, two sources familiar with the move said on Friday. Sinenko, widely considered one of the top gasoline traders, was poached by Gunvor from Noble Group at the end of 2017 as...
Lexicon Pharmaceuticals Files $200 Million Mixed Shelf
Lexicon Pharmaceuticals Files $200 Million Mixed Shelf
Aug 2, 2024
10:45 AM EDT, 08/02/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to $200 million of its securities from time to time. The filing covers common and preferred shares, debt securities, warrants, rights, and units. Net proceeds from any such sale will...
Amylyx Pharmaceuticals' Receives EU Orphan Designation for Potential Wolfram Syndrome Drug
Amylyx Pharmaceuticals' Receives EU Orphan Designation for Potential Wolfram Syndrome Drug
Aug 2, 2024
10:50 AM EDT, 08/02/2024 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) said Friday it has received orphan drug designation from the European Commission for AMX0035 as a potential treatment for Wolfram syndrome. The designation was granted following a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products, the company said. Amylyx said it expects to report...
CME Group Reports Record Average Daily Volume for July
CME Group Reports Record Average Daily Volume for July
Aug 2, 2024
10:49 AM EDT, 08/02/2024 (MT Newswires) -- CME Group ( CME ) said Friday that it set a new average daily volume record of 24.8 million contracts for July, up 24% from a year earlier. The derivatives marketplace said its interest rate and metals products also set a new average daily volume record for July, and that its US Treasury...
Copyright 2023-2026 - www.financetom.com All Rights Reserved